SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > Billion dollar annual opportunity yet no real effort to tell

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Apr 05, 2022 10:59am

108 Views

Post# 34576630

RE:RE:Billion dollar annual opportunity yet no real effort to tell

Here is what I would say. What, realistically, does the market know about this play and how?
It's owned by 3 wealthy investors, a handful of insiders, and likely a few dozen early retail investors that somehow have stumbled accross it (likely a few savvy US players as well)

There is a switch that needs to be flipped. I'm pretty sure it hasn't slipped their minds...that they will eventually need exposure to create a bid, and gain liquidity. The short term financing is a low-risk formality IMO, with so much at stake. No one (ie the majority owners) will let the Company default on a debt obligation with so much potential ahead of them.

Re the PBI acquisition, I don't expect Feb Mar to be as good as Jan (due to PCR testing waning following the initial omicron spike), but there is no market (yet) for the shares. Nor is there any expectation. Q2 (Q1 calendar) will look impressive by past SQI top-line standards, once newbies bother to look.

When does the IR switch get flipped? When does Cinderella (SQI) get introduced to the Prince (US Biotech market = 50 times larger than Canada's) ? That is what I want to know. Insiders, early adoptors, savvy US investors, generally "aware" US investors found via IR, then the masses. That is the progression path...or at least that is what I hope it is.

Share consolidation, in all likelihood, will occur later, after the "flip switchiing exercise, and after an initial run....IMO, and if I was a betting man.

MM

25Stone7859 wrote: Is SQI making any money currently though the four hubs on Lung transplantation? I doubt it. Sqi intends to seek FDA approval in the 2nd half of 2022 for the technology but why the delay if this is such a big deal ? I think there is potential but your posts are are too optomistic given that they have not even submitted.
Also the news is out on Antibody testing and AZOVA but there are no buyers at US 0.14.
SQI has to re-finance the PBI acquisition by April 14th but how ? Perhaps income in Feb/March will help but SQI is not heralding this as they did with Jan. un-audited results. How come? Maybe the results were less than expected.
And then we are going to experience a share consolidation. Usually, they don't work out for the shareholders.
Lots of icebergs on offer at these prices.
Has anyone contacted Morris ?